Table 1 Different characteristics and schedule of CD20xCD3 bispecific antibody in B-cell lymphomas.
From: Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives
Construct | Format | Technology | Route (Max rec. dose) | Schedule | No. of cycles | Indication | ORR / CR rate % (No. pts) | FDA approval |
|---|---|---|---|---|---|---|---|---|
Mosunetuzumab | IGG1 | Knobs-into-Holes (different Fabs) | IV (30 mg)/ SC (45 mg) | SUD: 1 mg C1D1, 2 mg C1D8, 60 mg C1D15, 60 mg C2D1, 30 mg C3D1 + every 21 days | 8 cycles if CR – up to 17 cycles if PR or SD | R/R FL ≥ 2 lines of tx | 80/60 (90) | Dec 2022 |
Glofitamab | IGG1 | Head-to-tail fusion | IV (30 mg) | Obinutuzumab pretreatment 1000 mg, SUD 2.5 mg C1D8 – 10 mg C1D15 – 30 mg C2D1 every 21 days | Max 12 cycles | R/R DLBCL ≥ 2 lines of tx | 56/43 (132) | June 2023 |
Epcoritamab | IGG1 | Controlled Fab-arm exchange | SC (48 mg) | SUD: 0.16 mg C1D1, 0.8 mg C1D8, 48 mg C1D15 once weekly on C1-3, Q 2 weeks C4-9, Q 4 weeks C10+ | Until disease progression or toxicity | R/R DLBCL ≥ 2 lines of tx | 61/38 (157) | May 2023 |
Odronextamab | IGG4 | Heavy chains with different affinity | IV (320 mg) | 0.7 mg split: 0.2 mg C1D1/0.5 mg C1D2, 4 mg split: C1D8/D9, 20 mg split: C1D15/D16, 160 mg C2D1 weekly until C4. 320 mg Q 2 weeks C5+ | Until disease progression or toxicity | R/R DLBCL or FL ≥ 2 lines of tx | DLBCL: 49/31 (130) FL: 82/75 (121) | Marketing authorization application EMA |
Plamotamab | IGG1 | Fab-Fc x scFv-Fc | IV (50 mg) | Cycle 1: 0.8 / 2 / 20 / 35 mg QW Cycle 2: 50 mg QW; Cycle 3 onward: 50 mg Q2W | Until disease progression | Mixed R/R B-NHL | NA | NA |
IGM 2323 | IGM | IgM + modified J chain | IV (0.5–1000) | Days 1, 8, and 15 of 21-day cycles | Until disease progression | R/R B-NHL | N/A | N/A |
